Skip to main content

Cambrex invests in Sweden

Small molecule CDMO Cambrex is to spend $3.6 million to increase flexible drug substance manufacturing capacity by 6 m3 (25%) at Karlskoga, Sweden, in response to growing demand for commercial-scale API manufacturing. Engineering work has already commenced and should be completed by November.

Change at the top for CDMOs

Two of the major global pharmaceutical CDMOs, Lonza and Alcami, have announced the appointments of new CEOs in early June. There have also been changes in senior positions at Corden Pharma and, imminently, at Cambrex.

Permira buys Cambrex

Cambrex has signed a definitive agreement to be acquired by an affiliate of private equity firm Permira, which has $48 billion of committed capital in its portfolio, covering healthcare among four other sectors.
Subscribe to Cambrex

 

 

 

AMRI banner advert